154 related articles for article (PubMed ID: 38007714)
1. Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment.
Minichmayr IK; Wicha SG; Matzneller P; Kloft C; Zeitlinger M
Clin Pharmacokinet; 2024 Jan; 63(1):121-131. PubMed ID: 38007714
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
Riccobene TA; Carrothers TJ; Knebel W; Raber S; Chan PLS
Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279
[TBL] [Abstract][Full Text] [Related]
3. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.
Das S; Li J; Iaconis J; Zhou D; Stone GG; Yan JL; Melnick D
J Antimicrob Chemother; 2019 Feb; 74(2):425-431. PubMed ID: 30380060
[TBL] [Abstract][Full Text] [Related]
4. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
Van Wart SA; Ambrose PG; Rubino CM; Khariton T; Riccobene TA; Friedland HD; Critchley IA; Bhavnani SM
Antimicrob Agents Chemother; 2014; 58(2):885-91. PubMed ID: 24277021
[TBL] [Abstract][Full Text] [Related]
6. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
[TBL] [Abstract][Full Text] [Related]
7. Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil.
Matzneller P; Lackner E; Lagler H; Wulkersdorfer B; Österreicher Z; Zeitlinger M
Antimicrob Agents Chemother; 2016 Jun; 60(6):3617-25. PubMed ID: 27044549
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Bowker KE
Antimicrob Agents Chemother; 2013 Jun; 57(6):2451-6. PubMed ID: 23459495
[TBL] [Abstract][Full Text] [Related]
9. The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.
Chan PLS; McFadyen L; Quaye A; Leister-Tebbe H; Hendrick VM; Hammond J; Raber S
CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):551-563. PubMed ID: 33687148
[TBL] [Abstract][Full Text] [Related]
10. Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models.
Cristinacce A; Wright JG; Macpherson M; Iaconis J; Das S
Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115292. PubMed ID: 33360809
[TBL] [Abstract][Full Text] [Related]
11. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.
Cheng K; Pypstra R; Yan JL; Hammond J
J Antimicrob Chemother; 2019 Apr; 74(4):1086-1091. PubMed ID: 30597021
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis.
Autry EB; Rybak JM; Leung NR; Gardner BM; Burgess DR; Anstead MI; Kuhn RJ
Pharmacotherapy; 2016 Jan; 36(1):13-8. PubMed ID: 26748559
[TBL] [Abstract][Full Text] [Related]
14. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
[TBL] [Abstract][Full Text] [Related]
15. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
Biek D; Critchley IA; Riccobene TA; Thye DA
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations.
Martins FS; Martins JES; Severino P; Annaert P; Sy SKB
Br J Clin Pharmacol; 2023 Sep; 89(9):2726-2738. PubMed ID: 37005335
[TBL] [Abstract][Full Text] [Related]
17. Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.
Riccobene TA; Pushkin R; Jandourek A; Knebel W; Khariton T
Antimicrob Agents Chemother; 2016 Oct; 60(10):5849-57. PubMed ID: 27431215
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
[TBL] [Abstract][Full Text] [Related]
19. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
